$ATYR
aTyr Pharma Inc

2018 Q1 Form 10-Q Financial Statement

#000156459018013628 Filed on May 15, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.070M $5.890M $4.010M
YoY Change 1.5% 74.26% -2.67%
% of Gross Profit
Research & Development $6.150M $5.310M $9.204M
YoY Change -33.18% -41.9% -23.3%
% of Gross Profit
Depreciation & Amortization $184.0K $160.0K $226.0K
YoY Change -18.58% -27.27% -3.0%
% of Gross Profit
Operating Expenses $10.22M $11.20M $13.21M
YoY Change -22.64% -10.59% -18.02%
Operating Profit -$13.21M
YoY Change -18.02%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$447.0K -$270.0K -$194.0K
YoY Change 130.41% -792.86%
Pretax Income -$10.67M -$11.47M -$13.41M
YoY Change -20.43% -9.11% -16.66%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.67M -$11.47M -$13.41M
YoY Change -20.43% -8.69% -16.67%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.009M -$5.385M -$7.888M
COMMON SHARES
Basic Shares Outstanding 23.75M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $74.10M $85.12M $61.93M
YoY Change 19.64% 17.98% -27.98%
Cash & Equivalents $21.94M $21.09M $28.90M
Short-Term Investments $52.20M $64.03M $33.03M
Other Short-Term Assets $1.900M $1.900M $1.800M
YoY Change 5.56% -26.92% 12.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $76.00M $86.99M $63.80M
YoY Change 19.12% 16.29% -27.17%
LONG-TERM ASSETS
Property, Plant & Equipment $2.374M $2.280M $1.600M
YoY Change 48.38% 60.45% -11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $90.00K $90.00K $300.0K
YoY Change -70.0% -72.97% 200.0%
Total Long-Term Assets $2.470M $2.370M $1.900M
YoY Change 30.0% -58.6% -93.09%
TOTAL ASSETS
Total Short-Term Assets $76.00M $86.99M $63.80M
Total Long-Term Assets $2.470M $2.370M $1.900M
Total Assets $78.47M $89.36M $65.70M
YoY Change 19.44% 10.97% -42.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.462M $2.276M $1.200M
YoY Change 21.83% -12.66% -79.66%
Accrued Expenses $2.533M $3.103M $4.200M
YoY Change -39.69% -43.06% 16.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.027M $5.012M $1.094M
YoY Change 542.32% 1378.47% -67.82%
Total Short-Term Liabilities $11.02M $10.39M $6.549M
YoY Change 68.3% 21.89% -50.35%
LONG-TERM LIABILITIES
Long-Term Debt $12.95M $14.72M $8.480M
YoY Change 52.71% 60.02% 842.22%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $12.95M $14.72M $8.480M
YoY Change 52.71% 60.02% 1422.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.02M $10.39M $6.549M
Total Long-Term Liabilities $12.95M $14.72M $8.480M
Total Liabilities $23.97M $25.11M $15.03M
YoY Change 59.5% 41.68% 9.32%
SHAREHOLDERS EQUITY
Retained Earnings -$264.2M -$229.4M
YoY Change 22.32% 31.67%
Common Stock $30.00K $280.2M
YoY Change -99.99% 2.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $54.50M $64.25M $50.71M
YoY Change
Total Liabilities & Shareholders Equity $78.50M $89.36M $65.74M
YoY Change 19.42% 10.97% -42.9%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$10.67M -$11.47M -$13.41M
YoY Change -20.43% -8.69% -16.67%
Depreciation, Depletion And Amortization $184.0K $160.0K $226.0K
YoY Change -18.58% -27.27% -3.0%
Cash From Operating Activities -$10.58M -$10.30M -$13.89M
YoY Change -23.85% -11.89% 11.21%
INVESTING ACTIVITIES
Capital Expenditures $498.0K -$160.0K $262.0K
YoY Change 90.08% 220.0% -16.56%
Acquisitions
YoY Change
Other Investing Activities $11.91M -$3.370M $4.660M
YoY Change 155.58% -138.96% -68.32%
Cash From Investing Activities $11.41M -$3.530M $4.400M
YoY Change 159.41% -141.05% -69.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.000K $1.000K
YoY Change 700.0% -90.91%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.000K 5.160M 0.000
YoY Change -27.83% -100.0%
NET CHANGE
Cash From Operating Activities -10.58M -10.30M -13.89M
Cash From Investing Activities 11.41M -3.530M 4.400M
Cash From Financing Activities 8.000K 5.160M 0.000
Net Change In Cash 845.0K -8.670M -9.490M
YoY Change -108.9% -313.55% -986.92%
FREE CASH FLOW
Cash From Operating Activities -$10.58M -$10.30M -$13.89M
Capital Expenditures $498.0K -$160.0K $262.0K
Free Cash Flow -$11.08M -$10.14M -$14.15M
YoY Change -21.74% -12.89% 10.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
7027000
CY2018Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1462000
CY2018Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2533000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2374000
CY2018Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2018Q1 us-gaap Assets
Assets
78470000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5012000
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
11022000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10391000
CY2018Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12950000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14719000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2018Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
329455000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29828723
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29828723
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6150000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10684000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1277000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4070000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4007000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
10220000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13211000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-10667000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-13405000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29795466
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23739057
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13397000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
184000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
226000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
928000
CY2018Q1 us-gaap Accretion Expense
AccretionExpense
81000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328519000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q1 us-gaap Accretion Expense
AccretionExpense
37000
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
64000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-74000
CY2017Q1 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-81000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
40000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-776000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-999000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2792000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10577000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13888000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
498000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
262000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
7988000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
11489000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
19900000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
16150000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
11414000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4399000
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1000
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
845000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9488000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38388000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28900000
CY2018Q1 life Cash And Cash Equivalents And Available For Sale Investments
CashAndCashEquivalentsAndAvailableForSaleInvestments
74100000
CY2018Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2017Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
9039
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23755434
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4878731
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.02
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.21
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:6pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expense accruals. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
CY2018Q1 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Issuable in three separate tranches (the Term Loans), $10.0 million of which was funded in November 2016, $5.0 million of which was funded in June 2017 and $5.0 million of which was funded in December 2017.
CY2018Q1 life Noncancelable Operating Leases Term Of Expiration
NoncancelableOperatingLeasesTermOfExpiration
2019-05
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1256000
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25577969
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4617059
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1250761
CY2018Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3593
CY2018Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
20
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
259013
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.52
CY2018Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
CY2018Q1 life Available For Sale Securities In Gross Unrealized Loss Position Maturities Term Maximum
AvailableForSaleSecuritiesInGrossUnrealizedLossPositionMaturitiesTermMaximum
P12M
CY2017Q2 life Additional Lease Facility
AdditionalLeaseFacility
7411
CY2017Q2 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2017Q2 life Noncancelable Operating Leases Additional Commitment
NoncancelableOperatingLeasesAdditionalCommitment
700000
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
836000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
420000

Files In Submission

Name View Source Status
0001564590-18-013628-index-headers.html Edgar Link pending
0001564590-18-013628-index.html Edgar Link pending
0001564590-18-013628.txt Edgar Link pending
0001564590-18-013628-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805151846459975085.jpg Edgar Link pending
life-10q_20180331.htm Edgar Link pending
life-20180331.xml Edgar Link completed
life-20180331.xsd Edgar Link pending
life-20180331_cal.xml Edgar Link unprocessable
life-20180331_def.xml Edgar Link unprocessable
life-20180331_lab.xml Edgar Link unprocessable
life-20180331_pre.xml Edgar Link unprocessable
life-ex101_149.htm Edgar Link pending
life-ex311_10.htm Edgar Link pending
life-ex312_350.htm Edgar Link pending
life-ex321_7.htm Edgar Link pending
life-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending